{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Torres-Adorno AM"],"funding":["U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)","U.S. Department of Health & Human Services | NIH | National Cancer Institute","NCI NIH HHS"],"pagination":["2135-2150"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6430703"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["38(12)"],"pubmed_abstract":["Triple-negative breast cancer (TNBC), the most aggressive breast cancer subtype, currently lacks effective targeted therapy options. Eicosapentaenoic acid (EPA), an omega-3 fatty acid and constituent of fish oil, is a common supplement with anti-inflammatory properties. Although it is not a mainstream treatment, several preclinical studies have demonstrated that EPA exerts anti-tumor activity in breast cancer. However, against solid tumors, EPA as a monotherapy is clinically ineffective; thus, we sought to develop a novel targeted drug combination to bolster its therapeutic action against TNBC. Using a high-throughput functional siRNA screen, we identified Ephrin type-A receptor 2 (EPHA2), an oncogenic cell-surface receptor tyrosine kinase, as a therapeutic target that sensitizes TNBC cell"],"journal":["Oncogene"],"pubmed_title":["Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux."],"pmcid":["PMC6430703"],"funding_grant_id":["R01CA123318","P30 CA016672","R01 CA123318","R35 CA197707"],"pubmed_authors":["Tan L","Fan YY","Vitrac H","Eckhardt BL","Levental KR","Qi Y","Chapkin RS","Yang P","Ueno NT","Torres-Adorno AM"],"additional_accession":[]},"is_claimable":false,"name":"Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux.","description":"Triple-negative breast cancer (TNBC), the most aggressive breast cancer subtype, currently lacks effective targeted therapy options. Eicosapentaenoic acid (EPA), an omega-3 fatty acid and constituent of fish oil, is a common supplement with anti-inflammatory properties. Although it is not a mainstream treatment, several preclinical studies have demonstrated that EPA exerts anti-tumor activity in breast cancer. However, against solid tumors, EPA as a monotherapy is clinically ineffective; thus, we sought to develop a novel targeted drug combination to bolster its therapeutic action against TNBC. Using a high-throughput functional siRNA screen, we identified Ephrin type-A receptor 2 (EPHA2), an oncogenic cell-surface receptor tyrosine kinase, as a therapeutic target that sensitizes TNBC cell","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Mar","modification":"2026-05-03T22:04:52.462Z","creation":"2019-06-06T23:24:39Z"},"accession":"S-EPMC6430703","cross_references":{"pubmed":["30459358"],"doi":["10.1038/s41388-018-0569-5"]}}